Swiss Nuclear Doctors’ Post

PanMediso Spotlight｜Classification and Application of Medical Radioisotopes (II) Radioisotope therapy is a method of treating diseases using rays emitted by decaying radioisotopes. By selectively delivering radioisotopes to diseased tissues or cells, precise irradiation and destruction of diseased cells, and minimizing the effect on normal tissues can be achieved. Radioisotopes for Treatment. (1) emit only a-particles, beta-particles, Roche electrons, or are accompanied by the emission of only a small amount of weak gamma-rays. (2) Half-life from several hours to tens of days. (3) Radioactive agents with high specific activity can be obtained thereby. The therapeutic radioisotope Ac-225 with ideal half-life of 9.9d and high lethality of alpha rays, as well as the nuclear drug validity period of up to 120 hours, has a good therapeutic potential in the treatment of systemic micro-tumor foci, such as pancreatic cancer, prostate cancer, neuroendocrine tumors, and leukemias. As an international company dedicated to the ecosystem building of nuclear medicine, PanMediso Holdings provides GMP-grade production and global supply of new isotopes, in particular Ge-68 for diagnosis and Ac-225 for treatment, thereby bringing new power to the development of human health. #Ac225 #Radioisotope #68Ga #Radiotherapy

PanMediso Spotlight｜Classification and Application of Medical Radioisotopes (I) Medical radioisotopes play a vital role in modern medicine. They are widely used in the diagnosis and treatment of diseases, based on the type of rays, their sources and the diversity of clinical applications. Classification of medical radioisotopes Medical radioisotopes can be categorized in the following three dimensions: Types of rays: alpha isotopes, beta isotopes, gamma isotopes. Source: reactor prepared isotopes, gas pedal prepared isotopes, spent fuel extracted isotopes. Clinical uses: diagnostic isotopes, therapeutic isotopes. Diagnostic Isotopes Diagnostic radioisotopes are classified into three categories: function measurement, imaging and analysis. Since it is rapid, simple and painless as an examination method, it is easily accepted by patients and has been widely used in tumor diagnosis. Diagnostic radioisotopes are applied in SPECT, PET technology and its molecular imaging technology integrated with CT and MR, which have unique advantages in the precise diagnosis, staging, therapeutic efficacy evaluation and prognosis assessment of tumors. Application Value of 68Ga 68Ga, produced by the 68Ge-68Ga generator, is a radiotracer for PET, capable of labeling a wide range of biomolecules, and is widely used in tumor imaging, diagnosis of neurodegenerative diseases, and evaluation of cardiovascular diseases. 68Ga is one of the more widely used positronuclides in PET/CT, and is only second in frequency to 18F, with outstanding scientific research value and clinical significance. It has outstanding scientific research value and clinical significance. As an international company dedicated to the ecosystem building of nuclear medicine, PanMediso Holdings provides GMP-grade production and global supply of new isotopes, in particular Ge-68 and Ac-225. Asscientific research and innovation evolves, medical isotopes will further enhance the accuracy of medical imaging. #SPECT #PET #18F #Radioisotopes #68Ga #Ac225

Plasma assays are extremely exciting, because they promise to expand access to powerful #precision medicine tools. They are less expensive and easier to roll out with fewer geographic limitations than radio tracer-based #imaging tests. This begs the question as to what this means for imaging. I believe there is room for both: Imaging can provide answers that plasma assays just can’t deliver, such as the spatial distribution and amount of pathology. Additionally, their test/re-test noise is typically lower, thereby enabling better longitudinal tracking of disease progression (and hence measurement of therapeutic effect). Therefore, the future belongs to both modalities - plasma assays and imaging. They will provide #patient-centric diagnostic workflow solutions that are scalable and accessible to everyone. These are the reasons why I am so excited about our collaboration with Alamar Biosciences.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲: 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗮𝗻𝗱 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗚𝗲𝘁 𝗣𝗗𝗙 𝗦𝗮𝗺𝗽𝗹𝗲: https://lnkd.in/dmVJi87j 𝗨𝗻𝗹𝗼𝗰𝗸 𝗮 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗲𝘅𝗽𝗲𝗿𝘁 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗗𝗙 𝘀𝗮𝗺𝗽𝗹𝗲—𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲𝗹𝘆 𝗳𝗼𝗿 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗲𝗺𝗮𝗶𝗹 𝗵𝗼𝗹𝗱𝗲𝗿𝘀. 📧 Nuclear medicine is evolving rapidly, unlocking new frontiers in both diagnostics and therapeutics. In diagnostic nuclear medicine, techniques like PET and SPECT scans enable early and highly accurate detection of conditions across cardiology, neurology, oncology, pulmonology, and gastroenterology. These advancements are empowering physicians to make precise diagnoses, ultimately leading to better patient outcomes. With more refined imaging agents and digital tools, nuclear diagnostics is becoming indispensable in the early intervention and management of complex diseases. On the therapeutic side, nuclear medicine is paving the way for targeted treatments, particularly in oncology. Radiopharmaceuticals, which deliver radioactive isotopes directly to diseased cells, offer a breakthrough in cancer treatment by minimizing harm to surrounding healthy tissue. This approach is transforming how we treat not only cancer but also various neurological and cardiac conditions. As researchers continue to explore therapeutic applications, nuclear medicine promises safer, more personalized treatment options for patients. The future of nuclear medicine relies on continued innovation, interdisciplinary collaboration, and regulatory support. By pushing the boundaries of what's possible in diagnostic and therapeutic nuclear medicine, we can look forward to a healthcare landscape where diseases are detected sooner, treated more precisely, and managed with higher success rates. This transformative field is set to redefine the standards of care for years to come. #NuclearMedicine #MedicalInnovation #Diagnostics #Therapeutics #PrecisionMedicine #HealthcareTechnology #Oncology #Cardiology #Neurology #Radiopharmaceuticals #FutureOfHealthcare

🚀 Excited to announce that my research article  "𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗼𝗳 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝗰 𝗥𝗲𝘀𝗼𝗻𝗮𝗻𝗰𝗲 𝗔𝗴𝗲𝗻𝘁 𝗘𝗻𝘁𝗿𝗮𝗽𝗺𝗲𝗻𝘁 𝗙𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗥𝗲𝘃𝗲𝗿𝘀𝗶𝗯𝗹𝗲 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼" has just been published in Radiology and Oncology! This study researches principles of 𝗰𝗼𝗻𝘁𝗿𝗮𝘀𝘁 𝗮𝗴𝗲𝗻𝘁 𝗲𝗻𝘁𝗿𝗮𝗽𝗺𝗲𝗻𝘁 as non-invasive detection technique for 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻, offering promising future applications in research and medical diagnostics. 🧠 The use of contrast agent entrapment for 𝗠𝗥𝗜 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 could potentially revolutionize how we detect and assess 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗯𝗮𝘀𝗲𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀, making it a pivotal tool for both clinicians and researchers in the field. A big thank you to all the co-authors Damijan Miklavčič, Zala Vidic, Maria Scuderi, Igor Serša and Matej Kranjc for their invaluable contributions. Special thank you to Tamara Polajžer for fruitful discussion and insightful comments on this exciting topic. Check out the full article to explore the science behind this innovative approach! 🔬 #MRI #ContrastAgent #Electroporation #BiomedicalResearch #NonInvasiveDiagnostics #HealthcareResearch #Biophysics #InnovativeResearch https://lnkd.in/eMjYB3cb

This review explores the transformative potential of Artificial Intelligence AI in reshaping clinical trial methodologies, focusing on cardiovascular and oncological applications. Drawing insights from oncology, the article by C K, KW J, WW T 2019 delves into how AI could redefine clinical trials in cardiovascular medicine. Shifting the paradigm towards personalized medicine, the study highlights lessons learned and prospects for AI integration in cardiovascular research. The article by H, P S, A B, J H 2019 examines the role of AI in clinical trial design, emphasizing trends in pharmacological sciences. The review underscores the evolving landscape of AI applications, emphasizing its impact on optimizing trial design processes. Delso et al. 2021 present a comprehensive guide on designing AI driven clinical trials in Nuclear Medicine. The article addresses key considerations for implementing AI in this specialized field, offering insights into future directions and challenges. by Dr. A. V. Padmaja | Anusha Vemulapally | Jampula Srikanth "Personalized eProtocol Design: A Data-Driven Approach with AI" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-8 | Issue-1 , February 2024, URL: https://lnkd.in/dyvJfHrZ Paper Url: https://lnkd.in/d8ZQdhup

Feeling immense pleasure to share our recent work published in Biosensors and Bioelectronics. This study marks a breakthrough in Alzheimer’s disease (AD) diagnostics by developing a rapid, minimally invasive blood-based test that detects multiple AD biomarkers with high sensitivity using DNA nanotechnology based microfluidic chip biosensors. Our system can identify early signs of AD by quantifying specific biomarkers down to single molecule level , opening new doors for earlier and more accessible diagnosis. With AD being a leading cause of death and disability worldwide, traditional diagnostic methods can be invasive, costly, and limited in accessibility. Our approach offers a potential solution to these issues, enabling fast and precise biomarker analysis for AD risk assessment, progression tracking, and potentially treatment monitoring—all from a simple blood test. As we work toward validating this technology for broader clinical use, what are your thoughts on the role of non-invasive diagnostics in managing neurological diseases? Could this technology help transform the way we approach Alzheimer’s care? Article link: https://lnkd.in/g4fUrvAf #Alzheimer #Biosensing #DNA-nanotechnology #SERS #Microfluidics

🔬✨ Advances in Survival Prediction for SIRT Patients with Personalized Dosimetry ✨🔬 Another cutting-edge research from HUG - Hopitaux Universitaires de Genève, by Zahra Mansouri under the guidance of Prof. Habib Zaïdi and Prof. Valentina GARIBOTTO! Published in the European Journal of Nuclear Medicine and Molecular Imaging, this study investigates the role of clinical biomarkers and dosimetry parameters in predicting overall survival (OS) and progression-free survival (PFS) for patients with hepatocellular carcinoma (HCC) undergoing 90Y selective internal radiation therapy (SIRT). 🧬📈 🔹 Study Insights and Methodology: Using data from 17 HCC patients treated with personalized 90Y SIRT, the researchers analyzed voxel-wise dosimetry alongside 16 clinical biomarkers. The study utilized dose-volume constraints (DVCs) derived from 99mTc-MAA and 90Y SPECT/CT images, creating physical and biologically effective dose maps for tumors and liver tissues. Machine learning models applied multivariate analysis across eight different feature selection strategies to improve predictive accuracy. 📊🔬 🔹 Key Findings: High-Risk Predictors: Features like the presence of ascites, elevated ASAT (AST) levels, and specific dosimetry parameters (e.g., MAA-Dose-V205 for tumor-liver regions) were closely linked to OS and PFS. Predictive Power of ML Models: Machine learning models using selected biomarkers achieved a C-index of 0.94, suggesting high accuracy in stratifying patient survival based on therapy features. Impactful Dosimetry Parameters: Tumor coverage by doses exceeding 260 Gy showed potential for longer PFS, underscoring a link between absorbed dose and treatment efficacy. 👏 Congratulations to Zahra Mansouri, Yazdan Salimi, Prof. Zaidi, Dr. Mainta, and the Geneva team for advancing predictive modeling in personalized internal radiotherapy! 🔗 Read the full study: https://lnkd.in/e87-Rrgf #NuclearMedicine #SIRT #90YRadioembolization #GenevaUniversityHospital #MachineLearning #PersonalizedMedicine #MedicalImaging #Biomarkers

Congratulations to Nikolai Naoumov and Elaine Chng, PhD, on their newest review article! Read the full paper here: https://lnkd.in/gEfKYcRB --- Abstract Fibrosis represents a highly conserved response to tissue injury. Assessing fibrosis is central in diagnostic pathology, evaluating treatment response and prognosis. Second harmonic generation digital pathology with artificial intelligence analyses provides unparalleled precision and granularity in quantifying tissue collagen in its natural, unstained environment. This technology reveals new insights into the balance between fibrogenesis and fibrolysis, crucial in tracking disease evolution and treatment outcomes. This review describes applications of second harmonic generation digital pathology with artificial intelligence for detailed characterization of liver fibrosis, assessing treatment response in clinical trials, analyzing collagen features in other chronic diseases and cancers. Additionally, it offers a perspective on future developments in integrating various technologies into a comprehensive diagnostic workflow for more effective evaluation of therapy and disease prognosis.

 "𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗻𝗴 𝗚𝗿𝗼𝘄𝘁𝗵: 𝗧𝗵𝗲 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 #𝗡𝘂𝗰𝗹𝗲𝗮𝗿 #𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 " The Nuclear Medicine market is witnessing remarkable growth, valued at $82.78 billion in 2023 and projected to reach $244.02 billion by 2030, with a robust CAGR of 16.7%. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲? Nuclear medicine is a specialized branch of radiology that employs small amounts of radioactive materials (radionuclides) for medical research, diagnosis, and treatment, particularly in oncology. Unlike traditional imaging techniques, it provides critical insights into the function of organs and tissues, enabling targeted therapies and improved patient outcomes.  𝗙𝗼𝗿 𝗮 𝘁𝗵𝗼𝗿𝗼𝘂𝗴𝗵 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴, 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝘀𝘁𝘂𝗱𝘆 𝘃𝗶𝗮 𝘁𝗵𝗶𝘀 𝗹𝗶𝗻𝗸:https://lnkd.in/gaKerEeP Key Players Driving Innovation: GE HealthCare Siemens Healthineers Philips Cardinal Health Bayer | Pharmaceuticals Technological Advancements: GE Healthcare's StarGuide and NM/CT 870 CZT systems leverage advanced Cadmium Zinc Telluride (CZT) technology for superior imaging capabilities. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) continue to revolutionize diagnostic imaging, offering three-dimensional insights into various diseases, including cancer and cardiovascular conditions. Market Dynamics: Drivers: The increasing incidence of cancer and cardiovascular diseases, with 20 million new cancer cases reported in 2022. Technological advancements enhancing diagnostic accuracy and treatment efficacy. Market Segmentation: - Oncology: Leading application, emphasizing targeted therapies for cancer treatment. - Cardiovascular: Growing relevance due to the rising prevalence of cardiovascular diseases. Future Outlook: The Nuclear Medicine market is poised for substantial development, driven by rising disease prevalence and ongoing technological innovations. The WHO projects over 35 million new cancer cases by 2050, marking a 77% increase from 2022 estimates. Recent Developments: Strategic partnerships and acquisitions, such as between Lantheus Holdings and Perspective Therapeutics, are enhancing treatment options, especially for neuroendocrine tumors, while major players like Bayer AG expand their capabilities in targeted imaging and therapeutic radiopharmaceuticals. As we look ahead, the advancements in nuclear medicine offer a promising future for patient care and treatment efficacy. Let's connect to discuss how these innovations are shaping the healthcare landscape! #NuclearMedicine #HealthcareInnovation #Radiology #Oncology #CardiovascularHealth #MarketTrends #HealthTech